Literature DB >> 22373653

Association of influenza virus infection and inflammatory cytokines with acute myocardial infarction.

Xiuru Guan1, Wei Yang, Xijuan Sun, Lanfeng Wang, Benjiang Ma, Hongyuan Li, Jin Zhou.   

Abstract

OBJECTIVE: To explore the potential relationship between previous influenza virus (IV) infection and acute myocardial infarction (AMI), and the mechanism of atherosclerosis, we conducted a case-control study and examined inflammatory cytokines to assess the association of previous IV infection and AMI.
METHODS: A questionnaire-based survey was conducted to collect information about demographic characteristics and heart disease risk factors. Fasting blood samples were obtained to measure immunoglobulin (Ig) G antibodies to influenza virus A (IV-A), influenza virus B (IV-B), cytomegalovirus, herpes simplex virus type-1 and type-2, adenovirus, rubella virus and Chlamydia pneumoniae, and to measure the level of certain biochemistry markers: interleukin-2, 6, 10 and 18 (IL-2, 6, 10 and 18), tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ), endothelin-1 (ET-1), soluble intercellular adhesion molecule-1 (sICAM-1) and soluble vascular cell adhesion molecule-1 (sVCAM-1).
RESULTS: Compared with the controls, the cases were more likely to have positive IgG antibodies to IV-A and IV-B [IV-A: odds ratio (OR): 3.1, 95% confidence interval (CI): 1.5-6.4; IV-B: OR: 10.2, 95% CI: 5.7-20.0]. After adjustment for potential confounding variables, the risk of AMI was still associated with the presence of IgG antibodies to IV-A (adjusted OR: 5.5, 95% CI: 1.3-23.0) and IV-B (adjusted OR: 20.3, 95% CI: 5.6-40.8). The levels of IL-2, 6, 10 and18, TNF-α, IFN-γ, ET-1, sICAM-1 and sVCAM-1 in patients with AMI were significantly higher than those of the controls (P < 0.01).
CONCLUSIONS: Our study supports the hypothesis that previous IV infection is associated with AMI. Inflammatory cytokines may take part in the development of atherosclerosis and trigger the occurrence of AMI.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22373653     DOI: 10.1007/s00011-012-0449-3

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  35 in total

Review 1.  Influenza and cardiovascular disease: a new opportunity for prevention and the need for further studies.

Authors:  Mohammad Madjid; Morteza Naghavi; Silvio Litovsky; S Ward Casscells
Journal:  Circulation       Date:  2003-11-10       Impact factor: 29.690

2.  Multiple infections in carotid atherosclerotic plaques.

Authors:  B Chiu
Journal:  Am Heart J       Date:  1999-11       Impact factor: 4.749

Review 3.  Gamma interferon: a central mediator in atherosclerosis.

Authors:  M L Alfaro Leon; S H Zuckerman
Journal:  Inflamm Res       Date:  2005-10       Impact factor: 4.575

4.  Influenza virus directly infects, inflames, and resides in the arteries of atherosclerotic and normal mice.

Authors:  Mehran Haidari; Philip R Wyde; Silvio Litovsky; Deborah Vela; Muzammil Ali; S Ward Casscells; Mohammad Madjid
Journal:  Atherosclerosis       Date:  2009-07-24       Impact factor: 5.162

5.  Influenza vaccine pilot study in acute coronary syndromes and planned percutaneous coronary interventions: the FLU Vaccination Acute Coronary Syndromes (FLUVACS) Study.

Authors:  Enrique P Gurfinkel; Ricardo Leon de la Fuente; Oscar Mendiz; Branco Mautner
Journal:  Circulation       Date:  2002-05-07       Impact factor: 29.690

6.  Chlamydia pneumoniae, herpes simplex virus type 1, and cytomegalovirus and incident myocardial infarction and coronary heart disease death in older adults : the Cardiovascular Health Study.

Authors:  D S Siscovick; S M Schwartz; L Corey; J T Grayston; R Ashley; S P Wang; B M Psaty; R P Tracy; L H Kuller; R A Kronmal
Journal:  Circulation       Date:  2000-11-07       Impact factor: 29.690

7.  Association of influenza vaccination and reduced risk of recurrent myocardial infarction.

Authors:  M Naghavi; Z Barlas; S Siadaty; S Naguib; M Madjid; W Casscells
Journal:  Circulation       Date:  2000-12-19       Impact factor: 29.690

8.  High-density lipoprotein loses its anti-inflammatory properties during acute influenza a infection.

Authors:  B J Van Lenten; A C Wagner; D P Nayak; S Hama; M Navab; A M Fogelman
Journal:  Circulation       Date:  2001-05-08       Impact factor: 29.690

Review 9.  The role of C-reactive protein in atherosclerotic cardiovascular disease: an overview.

Authors:  Eleni S Nakou; Evangelos N Liberopoulos; Haralampos J Milionis; Moses S Elisaf
Journal:  Curr Vasc Pharmacol       Date:  2008-10       Impact factor: 2.719

Review 10.  Vascular cells contribute to atherosclerosis by cytokine- and innate-immunity-related inflammatory mechanisms.

Authors:  Harald Loppnow; Karl Werdan; Michael Buerke
Journal:  Innate Immun       Date:  2008-04       Impact factor: 2.680

View more
  20 in total

1.  Clinical aspects and cytokine response in adults with seasonal influenza infection.

Authors:  Jia-Rong Bian; Wei Nie; Yuan-Sheng Zang; Zheng Fang; Qing-Yu Xiu; Xing-Xiang Xu
Journal:  Int J Clin Exp Med       Date:  2014-12-15

2.  Statistical genetic analysis of serological measures of common, chronic infections in Alaska Native participants in the GOCADAN study.

Authors:  Rohina Rubicz; Jianhui Zhu; Sandra Laston; Shelley A Cole; V Saroja Voruganti; Sven O E Ebbesson; Barbara V Howard; Jean W Maccluer; Michael Davidson; Jason G Umans; Anthony G Comuzzie; Harald H H Göring
Journal:  Genet Epidemiol       Date:  2013-06-24       Impact factor: 2.135

Review 3.  Infectious burden and atherosclerosis: A clinical issue.

Authors:  Rosa Sessa; Marisa Di Pietro; Simone Filardo; Ombretta Turriziani
Journal:  World J Clin Cases       Date:  2014-07-16       Impact factor: 1.337

4.  Acute cardiac injury events ≤30 days after laboratory-confirmed influenza virus infection among U.S. veterans, 2010-2012.

Authors:  Alison Ludwig; Cynthia Lucero-Obusan; Patricia Schirmer; Carla Winston; Mark Holodniy
Journal:  BMC Cardiovasc Disord       Date:  2015-09-30       Impact factor: 2.298

5.  Gene Expression Profiles Link Respiratory Viral Infection, Platelet Response to Aspirin, and Acute Myocardial Infarction.

Authors:  Jason J Rose; Deepak Voora; Derek D Cyr; Joseph E Lucas; Aimee K Zaas; Christopher W Woods; L Kristin Newby; William E Kraus; Geoffrey S Ginsburg
Journal:  PLoS One       Date:  2015-07-20       Impact factor: 3.240

6.  A Matched Influenza Vaccine Strain Was Effective in Reducing the Risk of Acute Myocardial Infarction in Elderly Persons: A Population-Based Study.

Authors:  Shu-Yun Hsu; Fong-Lin Chen; Yung-Po Liaw; Jing-Yang Huang; Oswald Ndi Nfor; Day-Yu Chao
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

7.  Components of the interleukin-33/ST2 system are differentially expressed and regulated in human cardiac cells and in cells of the cardiac vasculature.

Authors:  Svitlana Demyanets; Christoph Kaun; Richard Pentz; Konstantin A Krychtiuk; Sabine Rauscher; Stefan Pfaffenberger; Andreas Zuckermann; Arezu Aliabadi; Marion Gröger; Gerald Maurer; Kurt Huber; Johann Wojta
Journal:  J Mol Cell Cardiol       Date:  2013-04-06       Impact factor: 5.000

8.  Ischaemic heart disease, influenza and influenza vaccination: a prospective case control study.

Authors:  C Raina Macintyre; Anita E Heywood; Pramesh Kovoor; Iman Ridda; Holly Seale; Timothy Tan; Zhanhai Gao; Anthea L Katelaris; Ho Wai Derrick Siu; Vincent Lo; Richard Lindley; Dominic E Dwyer
Journal:  Heart       Date:  2013-08-21       Impact factor: 5.994

9.  A Module Analysis Approach to Investigate Molecular Mechanism of TCM Formula: A Trial on Shu-feng-jie-du Formula.

Authors:  Jianglong Song; Fangbo Zhang; Shihuan Tang; Xi Liu; Yibo Gao; Peng Lu; Yanping Wang; Hongjun Yang
Journal:  Evid Based Complement Alternat Med       Date:  2013-11-26       Impact factor: 2.629

10.  Herpes Simplex Virus Type 1 and Type 2 Infection Increases Atherosclerosis Risk: Evidence Based on a Meta-Analysis.

Authors:  Yu Peng Wu; Dan Dan Sun; Yun Wang; Wen Liu; Jun Yang
Journal:  Biomed Res Int       Date:  2016-04-19       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.